Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cochlear mechanoreceptors refer to specialized hair cells in the cochlea that detect sound-induced vibrations via a complex mechanotransduction process.[5][1][2][3] These are not single protein targets, but rather sensory cells whose mechanosensitivity depends on a multi-protein complex, primarily the mechanically gated MET (mechanoelectrical transduction) ion channel complex in stereocilia. The MET channel likely includes or is regulated by several key proteins: transmembrane channel-like proteins TMC1/TMC2 (candidate pore-formers), LHFPL5 (TMHS), TMIE, cadherin 23 (CDH23), and protocadherin 15 (PCDH15), together with additional scaffold and regulatory elements such as harmonin, sans, and myosin VIIa[1][2]. Tip links formed by CDH23 and PCDH15 transmit mechanical force to open the MET channel when stereocilia bundles are deflected by sound, rapidly converting mechanical energy into an electrical signal (mechanoelectrical transduction)[1][2][3]. Dysfunction or mutation in any component can cause congenital deafness (e.g., Usher Syndrome, non-syndromic deafness)[2]. While aminoglycoside antibiotics like dihydrostreptomycin and gentamicin block these channels and cause hair cell death (ototoxicity), there are no approved drugs that positively target or modulate these receptors for therapy[2]. "Cochlear mechanoreceptors" does not refer to a single molecular entity, so this is not a canonical drug target and cannot be accurately mapped to a unique molecular structure or gene[1][2][3]. Key clarification: “Cochlear mechanoreceptors” is a broad anatomical/physiological term for a class of cells in the cochlea (hair cells containing a mechanotransduction complex), not a canonical molecule or validated drug target. The actual therapeutic targets are specific proteins (e.g., TMC1, PCDH15, CDH23, etc.) within the mechanotransduction apparatus[1][2].
Channel blockade (aminoglycosides block/inhibit the MET channel pore, causing hair cell toxicity and hearing loss)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cochlear hair cell mechanotransduction (MET) channel complex.